earnings
confidence high
sentiment neutral
materiality 0.70
Agios Q3 net loss $88.8M; mitapivat gets FDA Priority Review with PDUFA Feb 17, 2022
AGIOS PHARMACEUTICALS, INC.
2021-Q3 EPS reported
$27.19
- Net loss $88.8M vs $99.0M in Q3 2020; R&D $64.0M up from $51.9M on trial start-up costs.
- Cash $1.4B; expects to fund operations through cash-flow positivity without equity raise.
- FDA granted Priority Review for mitapivat in PK deficiency; PDUFA date Feb. 17, 2022.
- Initiated Phase 3 ENERGIZE and ENERGIZE-T for thalassemia; plan to start RISE UP sickle cell study by year-end.
- Repurchased 5.3M shares at $47.94 avg; $800M+ of $1.2B buyback completed.